Literature DB >> 10861011

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

O Neuhaus1, C Farina, A Yassouridis, H Wiendl, F Then Bergh, T Dose, H Wekerle, R Hohlfeld.   

Abstract

Copolymer 1 (COP), a standardized mixture of synthetic polypeptides consisting of l-glutamic acid, l-lysine, l-alanine, and l-tyrosine, has beneficial effects in multiple sclerosis and experimental autoimmune encephalomyelitis. We selected a panel of 721 COP-reactive T cell lines (TCL) from the blood of COP-treated and untreated multiple sclerosis patients and from healthy donors by using the split-well cloning technique. All TCL selected with COP proliferated in response to COP but not to myelin basic protein (MBP). Conversely, 31 control TCL selected with MBP proliferated in response to MBP but not to COP. We used intracellular double-immunofluorescence flow cytometry for quantitative analysis of cytokine production (IL-4, IFN-gamma) by the TCL. The majority of the COP-reactive TCL from untreated multiple sclerosis patients and normal donors predominantly produced IFN-gamma and, accordingly, were classified as T helper 1 cells (TH1). In contrast, the majority of the COP-reactive TCL from COP-treated patients predominantly (but not exclusively) produced IL-4-i.e., were TH2 (P < 0.05 as assessed by using a suitable preference intensity index). Longitudinal analyses revealed that the cytokine profile of COP-reactive TCL tends to shift from TH1 to TH2 during treatment. Interestingly, although there was no proliferative cross-reaction, about 10% of the COP-reactive TCL responded to MBP by secretion of small amounts of IL-4 or IFN-gamma, depending on the cytokine profile of the TCL. These results are consistent with a protective effect of COP-reactive TH2 cells. It is hypothesized that these cells are activated by COP in the periphery, migrate into the central nervous system, and produce immunomodulatory cytokines after local recognition of MBP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861011      PMCID: PMC16566          DOI: 10.1073/pnas.97.13.7452

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

2.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

Authors:  D Teitelbaum; C Webb; M Bree; A Meshorer; R Arnon; M Sela
Journal:  Clin Immunol Immunopathol       Date:  1974-11

3.  Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).

Authors:  U Brehm; S J Piddlesden; M V Gardinier; C Linington
Journal:  J Neuroimmunol       Date:  1999-06-01       Impact factor: 3.478

4.  Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals.

Authors:  M Pette; K Fujita; B Kitze; J N Whitaker; E Albert; L Kappos; H Wekerle
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

5.  A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

Authors:  M B Bornstein; A Miller; S Slagle; M Weitzman; H Crystal; E Drexler; M Keilson; A Merriam; S Wassertheil-Smoller; V Spada
Journal:  N Engl J Med       Date:  1987-08-13       Impact factor: 91.245

6.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  Low dose ultraviolet B-irradiated Langerhans cells preferentially activate CD4+ cells of the T helper 2 subset.

Authors:  J C Simon; P D Cruz; P R Bergstresser; R E Tigelaar
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

9.  T helper cells grown with hapten-modified cultured Langerhans' cells produce interleukin 4 and stimulate IgE production by B cells.

Authors:  C Hauser; C M Snapper; J Ohara; W E Paul; S I Katz
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

10.  Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.

Authors:  M Krogsgaard; K W Wucherpfennig; B Cannella; B E Hansen; A Svejgaard; J Pyrdol; H Ditzel; C Raine; J Engberg; L Fugger; B Canella
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  78 in total

Review 1.  Degeneracy, as opposed to specificity, in immunotherapy.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 2.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

Authors:  R Aharoni; D Teitelbaum; O Leitner; A Meshorer; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 4.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 5.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

6.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

7.  Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.

Authors:  Alexander M Herrmann; Kerstin Göbel; Ole J Simon; Nico Melzer; Michael K Schuhmann; Max-Philipp Stenner; Andreas Weishaupt; Christoph Kleinschnitz; Stefan Bittner; Patrick Meuth; Olaf Stuve; Thomas Budde; Bernd C Kieseier; Heinz Wiendl; Sven G Meuth
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

8.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

Authors:  Jian Hong; Ningli Li; Xuejun Zhang; Biao Zheng; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

9.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

Review 10.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.